NasdaqGM - Nasdaq Real Time Price USD

Climb Bio Inc (CLYM)

Compare

1.1600

-0.0450

(-3.73%)

At close: April 10 at 4:00:02 PM EDT

1.2100

+0.05

+(4.31%)

After hours: April 10 at 7:45:52 PM EDT

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX

By Exec Edge Editorial Staff Exec Edge today announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes […]

Exec Edge 11 hours ago

CLYM
-3.73%
REX

FLD
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent DirectorsWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Boar

GlobeNewswire 9 days ago

VERV

IUGNF

ABOS
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025. 24th Annual Needham Virtual Healthcare Conference Format: Presentation and one-on-one investor meetingsDate: April 10, 2025Time: 8:45 a.m. ETWebcast: Click here About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeu

GlobeNewswire 14 days ago

CLYM
-3.73%
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

Visit Exec Edge Research for Full Report By Exec Edge Research Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025. As we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an […]

Exec Edge 15 days ago

CLYM
-3.73%
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) Completed Studies to Support Process Optimization through Cell Line Switch for Budoprutug and Filed Additional Patent Applications to Further Strengthen Intellectual Property Position Expanded Pipeline to Include CLYM116, an Anti-APRIL (A PRoliferation-Inducing Ligand) Monoclonal Antibo

GlobeNewswire 16 days ago

CLYM
-3.73%
Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report

Visit Exec Edge Research for Full Report By Rayk Riechmann As one of the brightest emerging biotechnology companies, Climb Bio Inc. (NASDAQ: CLYM) aims to improve the efficacy of autoimmune disease treatment. With its recently acquired lead asset, Budoprutug, and exclusively licensed Anti-APRIL antibody, CLYM116, the innovative biotech play is positioned to pull ahead of […]

Exec Edge 21 days ago

CLYM
-3.73%
Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed below. TD Cowen 45th Annual Health Care Conference Format: Formal presentation and one-on-one investor meetingsDate: March 4, 2025Time: 9:50 a.m. ETWebcast: Click here Leerink’s Global Healthcare Conference 2025Format: Fireside chat and one-on-one investor meetings Date: March 10, 2025Time: 10:00 a.m.

GlobeNewswire last month

CLYM
-3.73%
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry. “I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team,” said Aoife Brennan, President and CEO of Climb Bio. “Perrin brings extensive experience and a track record of success across large ph

GlobeNewswire last month

CLYM
-3.73%
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually February 11-12, 2025. Oppenheimer 35th Annual Healthcare Life Sciences Conference Format: Presentation and one-on-one investor meetingsDate: February 12, 2025Time: 9:20 a.m. ETWebcast: Click here About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotech

GlobeNewswire 2 months ago

CLYM
-3.73%
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs Preclinical Data Expected to be Shared Later in 2025 WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070

GlobeNewswire 2 months ago

CLYM
-3.73%
Climb Bio to be Added to the Nasdaq Biotechnology Index

WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio’s inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq

GlobeNewswire 3 months ago

CLYM
-3.73%
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls Highlights Timing of Key Upcoming Milestones Cash Runway Remains through 2027 Expected to Enable Delivery of Key Value Inflection Points WELLESLEY HILLS, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Climb Bio, In

GlobeNewswire 4 months ago

CLYM
-3.73%
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his c

GlobeNewswire 4 months ago

CLYM
-3.73%
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trials in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELL

GlobeNewswire 5 months ago

CLYM
-3.73%
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024. Poster Presentation A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous NephropathyPresenter: Frank Cortazar, M.D., Director, New York Nephrology Vasculitis and Glomerular Center;Chi

GlobeNewswire 5 months ago

CLYM
-3.73%
Climb Bio to Host Virtual Investor Event on October 15, 2024

WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio’s management team and an external expert who will provide an update to the investment community on the Company’s strategy and focus on developing therapeutics for immune-mediated diseases. Climb Bio’s virtual investor event will include presentations from Aoife Brennan, M.B., Ch.B., President and C

GlobeNewswire 6 months ago

CLYM
-3.73%
Eliem Therapeutics Changes Name to Climb Bio

By Karen Roman Eliem Therapeutics, Inc. (Nasdaq: ELYM) said its new corporate name will be Climb Bio, Inc. and it will start trading at Nasdaq with the ticker symbol “CLYM” on Oct. 3. This rebranding reflects Climb’s laser-focused mission on tackling immune-mediated diseases, it said in a statement. Climb’s lead program is budoprutug (formerly TNT119), […]

Exec Edge 6 months ago

CLYM
-3.73%

Performance Overview

Return	CLYM	S&P 500 (^GSPC)
YTD	-35.56%	-10.43%
1-Year	-56.55%	+2.08%
3-Year	-86.11%	+17.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Climb Bio Inc (CLYM)

Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Climb Bio to be Added to the Nasdaq Biotechnology Index

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Climb Bio to Host Virtual Investor Event on October 15, 2024

Eliem Therapeutics Changes Name to Climb Bio

Performance Overview